1. INTRODUCTION {#sec1}
===============

Myocardial Ischemia is described as decreased blood supply to the myocardium causing lack of oxygen and decreased metabolite removal. Acute Myocardial Infarction (AMI) is the first lethal cause worldwide \[[@r1], [@r2]\]. Thus we need an earlier diagnosis in order to optimize the AMI therapy that would reduce the risk of heart failure. The electrocardiogram (ECG) has limited sensitivity (50-60%) in AMI detection. In addition, many biomarkers, such as creatine kinases (CK) cardiac troponins (cTns), and lactate dehydrogenase (LDH) are widely used in the diagnosis of acute myocardial infarction patients \[[@r3]\]. However, the delayed release of troponins reaching peak concentrations approximately 12-24 h after infarction remains a major problem delaying the early detection of AMI. Also, cardiac troponin is elevated in cardiac conditions other than myocardial infarction such as cardiac trauma and end stage renal disease \[[@r4]\]. Therefore, searching for novel biomarkers of high sensitivity as well as high accuracy for detection of AMI is a great challenge.

Several extracellular RNAs regulate the key processes linked to the pathogenesis of AMI. Many studies postulate that the expression of circulatory RNAs change over time and is affected by the duration and intensity of exposure to AMI risk factors, and may, therefore, be useful biomarkers in AMI diagnosis \[[@r5]\].

The ubiquitin Proteasome system (UPS) has been described as a way to remove the unwanted, or unneeded proteins \[[@r6]\]. It was recently found that in cardiac cells there are about nine ubiquitin ligases that act as critical players in common cardiac disease pathophysiology. Interestingly, some ubiquitin ligases, such as MDM2 and CHIP target p53 leading to proteasomal degradation and thereby protecting cardio myocytes against apoptosis in ischemia reperfusion (I.R) injury cases \[[@r7], [@r8]\]. *ANPCII* gene is an E3 ubiquitin-protein ligase complex (a member of the anaphase promoting complex) which regulated through the cell cycle being a part of The UPS (The ubiquitin proteasome system). *ANPC/C* complex functions through ubiquitination and degradation of target proteins. It also recruits the E2 ubiquitin-conjugating enzymes to the complex \[[@r9]\].

Many miRNAs such as miRNA-34a, miRNA-208a, miRNA-210 and miRNA-495 were studied by many researchers and were found to be important gene regulators for angiogenesis and UPS in AMI. Consequently, they are considered to be important therapeutic tools particularly for the prevention of heart failure after AMI \[[@r10], [@r11]\]. Hence, this highlights the emergence of miRNAs as sensitive biomarkers of AMI and their possible use as new biomarkers for diagnosis and therapeutic targeting of AMI being stable in plasma, serum, and urine, as well as their cell-specific physiological functions \[[@r12], [@r13]\].

On the other hand, long noncoding RNAs (lncRNAs) were suggested by other researchers to have an association with cardiac ischemia \[[@r14], [@r15]\]; *e.g*; myocardial infarction-associated transcript, potassium voltage-gated channel, *KQT*-like subfamily HOX antisense intergenic RNA and *long noncoding RNA HOTAIR* which was found to have a protective effect in cardiac tissue and that the extracellular *HOTAIR* may be a promising biomarker for AMI detection \[[@r16]-[@r18]\].

In this study, we hypothesize that the chosen RNAs by *in silico* data analysis are related to UPS system and specific to AMI might be a potential biomarker panel for the detection of AMI. We first chosen AMI specific genes and linked to UPS system and their master regulators at epigenetic level through *in silico* data analysis. Then, to investigate this panel, we assessed whether *lncRNA-RP11-175K6, microRNA-106b-5p(miR-106b-5p)* and anaphase promoting complex subunit 11 (*ANAPC11*) mRNA showed significantly differential expression in sera of AMI group compared to non-cardiac chest patients and healthy volunteers.

2. PATIENTS AND METHODS {#sec2}
=======================

The Ethical Committee at Ain Shams faculty of medicine granted this Pilot study an approval. The study includes 69 Egyptian patients with acute myocardial infarction at the Cardiovascular Department, Ain Shams University hospitals, 31 patients with angina pectoris, but without MI and non-cardiac chest pain according to the outcome of coronary angiography (non-cardiac causes due to gastrointestinal or lung or any other chest condition) and 31 healthy normal volunteers who have normal ECG, without any history of cardiovascular disease and were visiting the hospital for regular health checkups with matching sex and age to the patients' groups after taking an informed consent. The enrolled participants were in the period from April 2017 till October 2017. AMI diagnosis was performed through evaluating the elevated serum troponin levels, CK-MB in addition to history and clinical symptoms consistent with cardiac ischemia within 6 hours of chest pain. AMI was diagnosed on the basis of a combination of several parameters: ischemic symptoms, a pathological Q wave and elevated cTnI (cardiac troponin I) with CK-MB (creatine kinase-MB) expression. All AMI patients were diagnosed for the first time and underwent primary PCI. The patients were diagnosed according to guidelines that were adopted from American College of Cardiology/American Heart Association (2018 ESC/ACC/ AHA/WHF Fourth Universal Definition) and two independent cardiologists judgment were considered. The exclusion criteria for this study were patients with a history of end-stage renal failure, hepatitis, hepatic failure, cardiomyopathy, bleeding disorders, autoimmune diseases, previous irradiation therapy to the thoracic region, arthritis or inflammatory bowel disease (IBD), chronic muscle disorders and malignancy.

Within the first 6 hours of onset of chest pain blood samples were collected for continuous assessment of cardiac markers; CK --MB and hs-cTnT. Centrifugation was done at 3,000 rpm for 15 min, separating the sera samples then it was aliquoted and eventually kept at -80°C.

2.1. Bioinformatics' Analysis {#sec2.1}
-----------------------------

The selection of these genes firstly, focused on the literature search that ensured the ubiquitin Proteasome system (UPS) dysregulation in acute myocardial infarction. Secondly, the Gene Expression Omnibus (GEO). Gene atlas expression, Gene card database, UniProt and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment network analyses were performed to understand the potential molecular mechanisms linking UPS dysregulation to AMI pathogenesis to select anaphase promoting complex subunit 11 (*ANAPC11*) due to the following causes, linked to UPS, specific to AMI, novelty, high expression in normal cardiac tissue (Supplementary Figs. **1-5**). Thirdly, miR-106b-5p has been selected as a target to ANAPC11 mRNA due to higher number of complementarity binding site, linked to UPS dysregulation, related to cardiac injury as the pathway enrichment analysis which revealed that miR-106b-5p is linked to endocytosis, TGF-beta signaling pathway, MAPK signaling pathway, Ubiquitin mediated proteolysis (Table **[1](#T1){ref-type="table"}**, Supplementary Figs. **6-8**). Lastly, lncRNA-RP11-175K6.1 (LOC101927740) was identified to control the expression of the above genes by accessing a database of lncRNAs that act as ceRNAs (starbase database). We have selected lncRNA-RP11-175K6.1 based on novelty and presence of higher miRNA binding sites. We have also validated the alignment between lncRNA-RP11-175K6.1-miRNA 106b by using Claustal tool in European bioinformatics institute thus verifying the *in silico* prediction that lncRNA-RP11-175K6.1-miRNA 106b target ANapc11mRNA (Supplementary Figs. **9** and **10**).

2.2. Purification of Total RNA Including miRNA and Reverse Transcription {#sec2.2}
------------------------------------------------------------------------

The extraction step of RNAs from sera sample was performed using miRNEasy RNA isolation kit (Qiagen, Hilden, Germany) as reported by manufacturer. 30µl of nuclease-free water was added to every RNA samples. NanoDrop spectrophotometer (Thermo Scientific, USA) \[[@r19]\] was used to get the concentration and purity of RNA. cDNA for mRNAs, lncRNA and miRNA were synthesized by miScript II RT Kit (Qiagen, Germany) in Rotor gene Thermal cycler (Thermo Electron Waltham, MA).

2.3. Differential Expression of the Selected RNAs by Real Time-Qrt PCR {#sec2.3}
----------------------------------------------------------------------

*ANPCII* mRNA and lncRNA-RP11-175K6 expressions in sera samples were quantified by using QuantiTect SYBR Green PCR Kit and RT^2^ SYBR Green ROX qPCR Mastermix, sequentially. RT^2^ lncRNA qPCR Assay for Human lncRNA-RP11-175K6.1(LOC101927740 (ENST00000499 583) and ANPCII QuantiTect Primer Assay (NM\_ 001002244), Hs_ACTB_1\_SG QuantiTect Primer Assay (NM_001002244) \[that was used as housekeeping gene in equalization of raw data\] were purchased from Qiagen, Germany.

We used miScript SYBR Green PCR Kit (Qiagen /SABiosciences Corporation, Frederick, MD) for quantification of hsa-\_ miR106b-5p expression in different sera samples using either Hs\_ miR106_1 miScript Primer Assay targets mature miRNA: hsa- miR106 - MIMAT0000680: 5\'UAAAGUGCUGACAGUGCAGAU and snord68 that was used as housekeeping gene, Each reaction was done in duplicate. Relative quantification of RNAs expression was calculated by using the method of Leviak RQ= 2^-ΔΔCt^ method \[[@r19]\].

Data analysis was performed using the Rotor Gene real time PCR (Qiagen, Hilden, Germany) which is considered negative if higher than 36 Ct value.

2.4. Statistics {#sec2.4}
---------------

The data was statistically analyzed using SPSS22. Krausakul Wallis test, chi-square test, and Spearman correlation test were used as appropriate. The receiver operating characteristic (ROC) curve was done to characterize the predictive value of the selected RNAs for AMI.

3. RESULTS {#sec3}
==========

3.1. Clinical and Laboratory Data of the Study {#sec3.1}
----------------------------------------------

In this study, we have not found any differences among the three investigated groups *i.e.*, age, sex and smoker: nonsmoker ratio (p\>0.05), but in serum creatinine, total Triglycerides and cardiac troponin I showed marked differences and the details are shown in (Supplementary Table **1**).

3.2. Differential Expression of Serum RNAs Among the Study Groups {#sec3.2}
-----------------------------------------------------------------

We confirm our *in silico* data regarding the relationship between the three chosen RNAs by measuring the serum levels of the three RNAs in the study samples. We assessed the RNAs based on the fold change (RQ) values. We found that the AMI group had down regulated both *lncRNA-RP11-175K6.1* and RQ-*ANPCII* mRNA with concomitant up regulation of RQ-*miR-106b-5p* in comparison with the 2 control groups (p\<0.01) (Supplementary Table **2**, Fig. (**1**).

Comparing AMI group to non-cardiac chest pain patients and healthy control participants by ROC curve analysis shows that the best cutoff values of *lncRNA-RP11-175K6.1*, *ANPCII* mRNA and RQ-*miR-106b-5p* were 1.36, 0.9950 and 10.94, respectively. The measured sensitivities were found to be 97.1%, 82.6% and 100%, respectively. These results indicate that these cutoff values could be used to differentiate AMI group form non cardiac chest pain patients and enrolled healthy people as illustrated in Fig. **[2(a-c)](#F2a){ref-type="fig"}** and Tables **[2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**.

3.3. Correlation between Serum RNAs with the Clinicopathological Factors in AMI Group {#sec3.3}
-------------------------------------------------------------------------------------

There was no significant correlation between any of the investigated serum RNAs and clinicopathological factors in the AMI group except serum *ANPCII* mRNA expression levels with diabetes mellitus and serum *miR-106b* expression levels with smoking, sex, nitrate, blocker, ACEI and statin use; *lncRNA-RP11-175K6.1* expression levels with age, smoking, blockers, nitrate ACEI usage (Supplementary Table **3**).

Significant positive correlation was found between *lncRNA-RP11-175K6.1* and *ANPCII mRNA* among the study groups (p\<0.05) (Supplementary Table **4**). Moreover, there was a significant inverse correlation between hsa-miRNA-106b-5p and *lncRNA-RP11-175K6.1* and *ANPCII mRNA* levels (r = -0.687, p\<0.01 and r = -0.653, p\<0.01, respectively). Remarkably, there was a significant direct correlation between hsa-miR-106b-5p and cardiac troponin I and CK-MB. There was a negative correlation between *ANPCII mRNA*, *lncRNA-RP11-175K6.1* and cardiac Troponin I level.

Regression analysis revealed that serum *miR-106b-5p* was a strong independent predictor of AMI occurrence (all p\<0.01) (Supplementary Table **5**).

4. DISCUSSION {#sec4}
=============

AMI can lead to congestive heart failure and malignant arrhythmia causing high morbidity and mortality \[[@r19]\]. Therefore, in order to provide optimized benefits to current therapies, it is necessary to identify novel, highly sensitive and specific biomarkers and their regulatory targets for the early detection of AMI. Long intergeinc non coding RNAs and microRNAs have been widely investigated as potential disease biomarkers and therapeutic targets \[[@r19]\]. This could be attributed to their relative higher stability as they can resist the degradation process mediated by RNase enzymes \[[@r20]\].

By using an integrated genetic epigenetic approach, we identified the level of expression of *lncRNA-RP11-175K6.1*(LOC101927740), *ANPCII mRNA* and *miR106 b-5p* and were found to be strongly detected in the serum of AMI patients making them potential biomarkers in diagnosing such polygenic diseases. It is supposed that the high performance requirement of AMI diagnosis does not depend upon single gene biomarker approach, so finding a network of genes that are functionally linked to each other may raise the success percentage of AMI diagnosis in comparison to conventional single-marker approach.

Ubiquitin ligases (E3s), as part of the UPS, are the master players that direct the ubiquitin addition to the target proteins and thus changing their physical properties or decreasing their activity but most importantly mark them for degradation \[[@r21], [@r22]\]. The cardiomyocyte-specific ubiquitin ligases have been extensively studied and revealed novel functional roles for each of them \[[@r23]\]. ANPCII (Anaphase-promoting complex subunit 11) APC/C core complex is a cell cycle-regulated E3 ubiquitin ligase showing a high expression in heart and skeletal muscle and moreover its activators play a major role in symbiotic interactions, hormone signaling and gametogenesis \[[@r24]\]. Furthermore, the high expression of ANPCII mRNA is associated with chromosomal instability and residual tumor and lymphovascular invasion \[[@r25]\]. The overexpression of APC7 was also strongly related to primary colorectal cancer (CRC) and so it can be utilized as a potential novel biomarker of metastatic CRC \[[@r26]\].

Interestingly, Luo *et al.*, found an inverse correlation between ITCH E3 ubiquitin ligase and miRNA-106b and in pancreatic cancer \[[@r27]\]. Moreover, miR-106b was found to have a high expression level in myocardial infarction together with an angiogenesis anti-apoptotic role in cardiomyocytes through inhibition of p21 expression \[[@r28], [@r29]\]. It is reported that microRNA-106 constitutes a cluster of 25 especially miR- 106b which is significantly increased in patients with colorectal cancer \[[@r11]\], hepatocellular carcinoma \[[@r30]\], gastric cancer \[[@r31]\] prostate cancer \[[@r32]\] and renal cancer \[[@r33]\].

LncRNAs are stable in plasma and show disease and tissue specificity \[[@r34]\]. More than 1000 lncRNAs have been linked to various crucial processes, including growth, UPS, apoptosis, and cell proliferation \[[@r35]\]. *lncRNA-RP11-175K6* (*LOC101927740*) is located on the fifth chromosome with a strong relation with cardiomyocyte regeneration and angiogenesis \[[@r36]\]. *LncRNA-RP11-714G18.*1 has atheroprotective importance by suppressing vascular cell migration through RP11-714G18.1/LRP2BP/MMP1 axis expression \[[@r37]\].

Significantly, there was a direct correlation between *lncRNA-RP11-175K6.1* and *ANAPC11* mRNA (P\<0.05) with inverse correlation between *lncRNA-RP11-175K6.1, ANAPC11* mRNA and *miR-106b-5p.* We hypothesized that *lncRNA-RP11-175K6.1* could act as a sponge for *miR-106b-5p* with subsequent modulation of *ANAPC11* mRNA playing a potential role in AMI pathogenesis. *miR-106b-5p* seems to inhibit *ANAPC11* mRNA expression at transcriptional or posttranscriptional level (Fig. **[3](#F3){ref-type="fig"}**). Of note, there was inverse correlation found between *ANAPC11* mRNA and *lncRNA-RP11-175K6.1* and cardiac Troponin I level.

The study was limited by relatively small sample size from two centers in Egypt. Moreover, *in vitro* and *in vivo* mechanistic analysis is needed to clarify the deep mechanism of RNA-RNA crosstalk in AMI which are strongly recommended.

CONCLUSION
==========

We have identified dysregulation in the expression of serum *lncRNA-RP11-175K6/ miRNA -106b -5p* together with *ANAPC11* mRNA in AMI patients compared to the control groups. It may be a promising strategy for the development of an RNA based biomarker panel to discriminate AMI patients and non AMI patients. These findings may provide new tools and targets for AMI therapy. Further studies are highly recommended to detect serum (*lncRNA-RP11-175K6/ miRNA -106b -5p* - *ANAPC11* mRNA) in AMI patients' samples using nanoassay as a non-PCR based technique with many advantages *e.g.* direct detection of unamplified RNA network in sera samples for the early diagnosis of AMI patients, simple, rapid and cheap assay for these nucleic acids other than PCR.
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![Box plot shows relative expression of the serum RNAs between AMI and control groups. The data is presented as median fold changes (P\<0.05).](CG-20-340_F1){#F1}

![ROC curve analysis for lncRNA-RP11-175K6 used to calculate the best cut-off point to discriminate between the AMI and healthy groups. AUC \[SE\]=0.995 \[0.024\], 95% confidence interval=0.655-0.842, (*P*\<0.01).](CG-20-340_F2a){#F2a}

![ROC curve analysis for RQ-ANPCII mRNA used to calculate the best cut-off point to discriminate between the AMI and control groups. AUC \[SE\]=0.930 \[0.033\], 95% confidence interval=0.722-0.811, (*P*\<0.01).](CG-20-340_F2b){#F2b}

![ROC curve analysis for RQ-mIR-106b used to calculate the best cut-off point to discriminate between the AMI and control groups. AUC \[SE\]=0.995 \[0.038\], 95% confidence interval=0.845-0.931, (*P*\<0.01).](CG-20-340_F2c){#F2c}

![A schematic diagram to map the suggested association between the chosen genes. Schematic diagram of the study hypothesis.](CG-20-340_F3){#F3}

###### Gene ontology of *ANAPC11 mRNA.*

  S. No.   **ANapc11mRNA (retrieved from Pathways from BioSystems available at <https://www.ncbi.nlm.nih.gov/gene/51529>)**
  -------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  1\.      APC-Cdc20 mediated degradation of Nek2A, organism-specific biosystem (from REACTOME)
  2\.      APC/C complex, organism-specific biosystem (from KEGG)
  3\.      APC/C complex, conserved biosystem (from KEGG)
  4\.      APC/C-mediated degradation of cell cycle proteins, organism-specific biosystem (from REACTOME)
  5\.      APC/C:Cdc20 mediated degradation of Cyclin B, organism-specific biosystem (from REACTOME)
  6\.      APC/C:Cdc20 mediated degradation of Securin, organism-specific biosystem (from REACTOME)
  7\.      APC/C:Cdc20 mediated degradation of mitotic proteins, organism-specific biosystem (from REACTOME)
  8\.      APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1, organism-specific biosystem (from REACTOME)
  9\.      APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint, organism-specific biosystem (from REACTOME)
  10\.     Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins, organism-specific biosystem (from REACTOME)
  11\.     Adaptive Immune System, organism-specific biosystem (from REACTOME)
  12\.     Antigen processing: Ubiquitination & Proteasome degradation, organism-specific biosystem (from REACTOME)
  13\.     Autodegradation of Cdh1 by Cdh1:APC/C, organism-specific biosystem (from REACTOME)
  14\.     Cdc20:Phospho-APC/C mediated degradation of Cyclin A, organism-specific biosystem (from REACTOME)
  15\.     Cell Cycle, organism-specific biosystem (from REACTOME)
  16\.     Cell Cycle Checkpoints, organism-specific biosystem (from REACTOME)
  17\.     Cell Cycle, Mitotic, organism-specific biosystem (from REACTOME)
  18\.     Cell cycle, organism-specific biosystem (from KEGG)
  19\.     Cell cycle, conserved biosystem (from KEGG)
  20\.     Cellular Senescence, organism-specific biosystem (from REACTOME)
  21\.     Cellular responses to stress, organism-specific biosystem (from REACTOME)
  22\.     Class I MHC mediated antigen processing & presentation, organism-specific biosystem (from REACTOME)
  23\.     Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase, organism-specific biosystem (from REACTOME)
  24\.     HTLV-I infection, organism-specific biosystem (from KEGG)
  25\.     HTLV-I infection, conserved biosystem (from KEGG)

###### Positivity rate of serum investigated parameter based on fold change expression (RQ) among the study groups.

  ------------------------------------------------------------------------------------------------
  **-**                          ***miR106-b-5p***   ***ANPCII mRNA***   ***lncRNA-RP11-175K6***
  ------------------------------ ------------------- ------------------- -------------------------
  Acute myocardial infarction\   \                   \                   \
  Positive\                      N=69(100%)\         N=69(100%)\         N=2(2.8%)\
  Negative                       N=0(0.0%)           N=0(0%)             N=67(97.1%)

  Non cardiac chest pain\        \                   \                   N=1(3.2%)\
  Positive\                      N=1(3.22%)\         N=1(3.2%)\          N=30(96.77%)
  Negative                       N=30(96.7%)         N=30(96.77)         

  Control\                       \                   \                   N=1(3.2%)\
  Positive\                      N=0(0%)\            N=0(0%)\            N=30(96.77%)
  Negative                       N=31(100%)          N=31(100%)          

  P\                             \<.01\              \<.01\              \<.01\
  χ^2(a)^                        95.392              95.392              86.628
  ------------------------------------------------------------------------------------------------

###### Performance characteristics of serum investigated parameter based on fold change expression.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  **Biomarker**                      **Sensitivity**   **Specificity**   **PPV**\                          **NPV**\                          **Accuracy**
                                                                         **(Positive Predictive Value)**   **(Negative Predictive Value)**   
  ---------------------------------- ----------------- ----------------- --------------------------------- --------------------------------- --------------
  **All the study groups (n=131)**                                                                                                           

  *ANPCII mRNA*                      82.6%             96.8%             71.4%                             98.3%                             87%

  miR106-b-5P                        100%              96.8%             100%                              98.6%                             99%

  lncRNA-RP11-175K6                  97.1%             96.8%             93.8%                             98.5%                             97%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------
